Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al..  2018.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med. 378(8):731-739.

Knauf JA, Luckett KA, Chen K-Y, Voza F, Socci ND, Ghossein R, Fagin JA.  2018.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.. J Clin Invest. 128(9):4086-4097.

Belkacemi L, Atkins JL, Yang LU, Gadgil P, Sater AK, Chow DS, Bose RN, Zhang SXiaoliu.  2018.  Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly an Up-regulation of PEDF in Breast Cancer.. Anticancer Res. 38(2):623-646.

Harvey JD, Baker HA, Mercer E, Budhathoki-Uprety J, Heller DA.  2017.  Control of Carbon Nanotube Solvatochromic Response to Chemotherapeutic Agents.. ACS Appl Mater Interfaces. 9(43):37947-37953.

Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A.  2017.  Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.. Oncotarget. 8(8):14017-14028.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.  2017.  Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.. J Clin Oncol. 35(23):2692-2699.

Herting CJ, Chen Z, Pitter KL, Szulzewsky F, Kaffes I, Kaluzova M, Park JC, Cimino PJ, Brennan C, Wang B et al..  2017.  Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.. Glia. 65(12):1914-1926.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, S Kang P, Shankaran V et al..  2017.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.. J Clin Invest. 127(8):2930-2940.

Ivasyk I, Morgenstern PF, Wembacher-Schroeder E, Souweidane MM.  2017.  Influence of an intratumoral cyst on drug distribution by convection-enhanced delivery: case report.. J Neurosurg Pediatr. 20(3):256-260.

Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R et al..  2017.  A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.. Eur J Cancer. 83:229-236.

de Geus SWL, Eskander MF, Kasumova GG, Ng SChau, Kent TS, Mancias JD, Callery MP, Mahadevan A, Tseng JF.  2017.  Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.. Cancer. 123(21):4158-4167.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G et al..  2016.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.. Nat Med. 22(12):1488-1495.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM et al..  2016.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.. Nat Med. 22(12):1402-1410.

Fang J, Xiao L, Joo K-I, Liu Y, Zhang C, Liu S, Conti PS, Li Z, Wang P.  2016.  A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.. Int J Cancer. 138(4):1013-23.

Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HLeung.  2016.  Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.. J Mol Biol. 428(1):194-205.

Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP, Wood KC.  2016.  Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.. Sci Rep. 6:27696.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ et al..  2015.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.. Cancer Cell. 28(1):15-28.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney ASophia, Papalexi E et al..  2015.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.. Cancer Discov. 5(3):316-31.

Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S, Delord JPierre, Lacouture ME.  2014.  Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.. Breast Cancer Res Treat. 146(2):451-6.

Blachere NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M, Fak J, Monette S, Gantman EC, Frank MO et al..  2014.  T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.. Eur J Immunol. 44(11):3240-51.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A et al..  2011.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proc Natl Acad Sci U S A. 108(51):E1408-16.